Tibet Autonomous Region Clinical Research Center for High-altitude Stress, Endocrinology and Metabolism Disease, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, Sichuan, China.
Xizang Minzu University, Xianyang, China.
BMJ Open. 2024 Aug 24;14(8):e087142. doi: 10.1136/bmjopen-2024-087142.
Osteoporotic fractures are a leading cause of disability and contribute significantly to medical care costs worldwide. Variations in bone mineral density and the risk of osteoporosis are notably influenced by altitude. This study aims to longitudinally examine individuals with osteoporosis and low bone mass at three different altitudes (low, high and very high) to understand the effects of high-altitude environments on bone density.
This multicentre, prospective cohort study will involve 893 participants divided into three groups based on altitude: low (500-1500 m), high (2500-4500 m) and very high (4500-5500 m). Participants will undergo comprehensive diagnostic assessments, including demographic data collection, structured questionnaires, medical examinations and clinical laboratory tests. Follow-up visits will occur annually for a minimum of 5 years. The primary outcome will be changes in bone mineral density values. Secondary outcomes will include the incidence of osteoporosis and osteoporotic fractures. Cox proportional hazard models will be used to calculate the risk associated with osteoporotic events and related fractures.
The study has been approved by the Institutional Review Board of the Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (No: 2024-70). The acquired insights will be disseminated via academic forums, scholarly articles and stakeholder engagement sessions.
ChiCTR2300078872.
骨质疏松性骨折是导致残疾的主要原因，也是全球医疗费用的重要组成部分。骨密度和骨质疏松风险的变化明显受到海拔的影响。本研究旨在对三个不同海拔（低、中、高海拔）的骨质疏松和低骨量个体进行纵向研究，以了解高海拔环境对骨密度的影响。
这是一项多中心、前瞻性队列研究，将纳入 893 名参与者，根据海拔分为三组：低海拔（500-1500 米）、中海拔（2500-4500 米）和高海拔（4500-5500 米）。参与者将接受全面的诊断评估，包括收集人口统计学数据、结构化问卷、医学检查和临床实验室测试。随访将每年进行一次，至少持续 5 年。主要结局指标是骨密度值的变化。次要结局指标包括骨质疏松症和骨质疏松性骨折的发生率。将使用 Cox 比例风险模型计算与骨质疏松事件和相关骨折相关的风险。
该研究已获得成都市政府驻西藏自治区办事处人民医院伦理委员会的批准（编号：2024-70）。将通过学术论坛、学术文章和利益相关者参与会议传播所获得的见解。
ChiCTR2300078872。
